Japan’s Aska To Revamp Production Operations In Productivity Move
This article was originally published in PharmAsia News
Executive Summary
Aska Pharmaceutical says it plans to begin building a new $9.4 million production facility in April as part of a major expansion of its manufacturing operations. The new facility, in the Fukushima Prefecture, is expected to be ready to produce capsule drugs in two years, when Aska plans to close its Tokyo factory. As part of the overhaul, intended to allow greater productivity at lower costs, Aska also plans to form a joint venture with Akiyama Jozai to produce a line of hormone drugs. Hormone drugs and contraceptives account for nearly a third of Aska's sales. (Click here for more - a subscription may be required
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.